Clinical Trial Update: Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating selumetinib in adults with recurrent or refractory acute myeloid leukemia, including AML with t(15;17) and acute promye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3) | Phase 2 | Status: COMPLETED | Results posted: 2015-08-05